Treatment and outcomes of metastatic colorectal cancer in Australia: defining differences between public and private practice

Prior studies have suggested improved outcomes for cancer patients managed in private centres, despite universal healthcare within Australia.

[1]  Hartmut Link,et al.  FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial. , 2014, The Lancet. Oncology.

[2]  R. Schilsky,et al.  CALGB/SWOG 80405: Phase III trial of irinotecan/5-FU/leucovorin (FOLFIRI) or oxaliplatin/5-FU/leucovorin (mFOLFOX6) with bevacizumab (BV) or cetuximab (CET) for patients (pts) with KRAS wild-type (wt) untreated metastatic adenocarcinoma of the colon or rectum (MCRC). , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  Jinn Shiun Chen,et al.  Prognostic significance of the number of tumors and aggressive surgical approach in colorectal cancer hepatic metastasis , 2014, World Journal of Surgical Oncology.

[4]  P. Gibbs,et al.  Developing a national database for metastatic colorectal cancer management: perspectives and challenges , 2013, Internal medicine journal.

[5]  P. Gibbs,et al.  Financial incentives in cancer care and impact on prescribing practice. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  P. Gibbs,et al.  Patterns of care of elderly patients with metastatic colorectal cancer. , 2013 .

[7]  P. Gibbs,et al.  Is there a role for chemotherapy in metastatic colorectal cancer patients with a poor performance status , 2013 .

[8]  P. Gibbs,et al.  An initial watch and wait approach is a valid strategy for selected patients with newly diagnosed metastatic colorectal cancer. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[9]  P. Gibbs,et al.  ORIGINAL ARTICLE: Linking data from hospital and cancer registry databases: should this be standard practice? , 2010, Internal medicine journal.

[10]  N. Kemeny,et al.  Metastatic Colorectal Cancer: From Improved Survival to Potential Cure , 2010, Oncology.

[11]  P. Gibbs,et al.  Patient comorbidities and behaviour once diagnosed are major contributors to disparities in cancer health outcomes. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  B. Iacopetta,et al.  Comparing survival outcomes for patients with colorectal cancer treated in public and private hospitals , 2007, The Medical journal of Australia.

[13]  C. Holman,et al.  Colorectal cancer surgical care and survival: do private health insurance, socioeconomic and locational status make a difference? , 2005, ANZ journal of surgery.

[14]  C. Holman,et al.  Prostate cancer: socio‐economic, geographical and private‐health insurance effects on care and survival , 2005, BJU international.

[15]  D. Hendrie,et al.  The influence of socio-economic and locational disadvantage on survival after a diagnosis of lung or breast cancer in Western Australia , 2004, Journal of health services research & policy.

[16]  Gerard J Fitzsimmons,et al.  From the Australian Institute of Health and Welfare , 2014, Communicable diseases intelligence quarterly report.

[17]  J. Gold,et al.  Validation of a combined comorbidity index. , 1994, Journal of clinical epidemiology.